The Market Catalyst: The 51% Spend Crisis

By early 2026, biologics have become the primary economic driver of U.S. healthcare.  While these complex, large-molecule treatments represent only 5% of all prescriptions, they now account for an staggering 51% of total drug spending as of late 2025.  The U.S. biologics market is currently valued at approximately $203.6 billion, with projections indicating it will exceed $483 billion by 2034.

Commissioner Marty Makary has identified this concentration of spend as a systemic inefficiency, often referring to the high cost of biologics as a barrier to patient access.  In response, the FDA has initiated a pivot toward "Analytical Veracity."  For new biologics—particularly monoclonal antibodies (mAbs), which account for nearly 70% of the market share — the agency is beginning to replace multi-year human trials with advanced laboratory characterization and real-time monitoring.

The Evidence Gap: The High-Stakes Licensing Risk

As the FDA accelerates the approval of these molecules through the National Priority Voucher and other fast-track programs, the primary risk for manufacturers and clinicians moves from "regulatory approval" to "market sustainability".  When a biologic with a six-figure annual price tag is approved on an accelerated timeline, payers — both public and private — demand more than a preliminary snapshot; they demand Verified Clinical Veracity.

Legacy healthcare data systems fail this test.  Most existing data consists of Administrative Proxies (Data Exhaust) captured for billing, which lacks the clinical depth to prove long-term efficacy or address the "Measurement-to-Management Gap" that stalls value-based transitions.  Without Audit-Ready "Ground Truth", high-value biologics face the constant threat of "reimbursement limbo".

The Circle Solution: Building the Infrastructure of Evidence

The Circles platform provides the Regulatory-Grade Governance required to secure these high-valuation assets across any specialty, from oncology to immunology.  By defining the data architecture via Observational Protocols (OPs) before the biologic is administered, Circles ensure that every patient encounter generates a high-fidelity dataset.

Outcome Engineering:  Circles capture Standardized Longitudinal Scores (e.g., functional assessments and metabolic markers) at the point of care, providing the permanent audit trail necessary to justify premium pricing to payers.

Insurable Integrity:  By providing Verified Clinical Veracity, Circles create a "shield" for the clinical node, making billing errors or protocol deviations technically impossible and ensuring the data is ready for federal scrutiny.

Strategic Monopoly:  High-volume, high-veracity data sets within a Circle enable the use of Synthetic Control Arms (SCAs), which can supplement or even replace traditional clinical trials, creating a strategic advantage for manufacturers and clinical networks alike.

Strategic Outcome: Valuation via Tech-Enabled Assets

In the legacy model, biologics were a "pass-through" cost for clinics.  In the 2026 regulatory environment, the data generated by these treatments is the asset.  By utilizing Circles to provide Insurable Integrity, a Management Services Organization (MSO) reclassifies itself as a Tech-Enabled Asset.

This shift is the primary driver for Multiple Expansion, moving an organization from a standard 6–8x service multiple to a 12–15x asset multiple.  The value is no longer in the administration of the drug, but in the "Ground Truth" evidence that secures its place in the market.

‍Get involved or learn more — contact us today!

If you are interested in contributing to this important initiative or learning more about how you can be involved, please contact us.